SCHEMBL184818

SCHEMBL184818

O=C(O)c1cc(Oc2ccc(F)cc2)cc(C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
AKR1C3 P42330 1/20 0.52
CHEK2 O96017 1/20 0.49
NR4A2 P43354 2/20 0.49
PARP15 Q460N3 1/20 0.48
PARP10 Q53GL7 1/20 0.48
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
F2 P00734 1/20 0.48
PLG P00747 1/20 0.48
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
PRSS3 P35030 1/20 0.48
ST14 Q9Y5Y6 1/20 0.48
SRD5A2 P31213 2/20 0.47
S1PR2 O95136 2/20 0.45
PTGER4 P35408 1/20 0.45
PTGER2 P43116 1/20 0.45
SCN9A Q15858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29779473 0.90 KMT2A (0.65) MEN1KMT2AAKR1C3PARP15PARP10
SCHEMBL183373 0.89 KDM4E (0.52) MEN1KMT2AAKR1C3CHEK2F2
SCHEMBL3315939 0.86 BCL2L1 (0.65) KMT2ACHEK2NR4A2PARP15PARP10
SCHEMBL21652693 0.86 PARP10 (0.64) MEN1KMT2AAKR1C3PARP15PARP10
SCHEMBL2427519 0.84 AKR1C3 (0.77) AKR1C3NR4A2PARP15PARP10SRD5A2
SCHEMBL29762009 0.84 AKR1C3 (0.77) AKR1C3NR4A2PARP15PARP10SRD5A2
SCHEMBL15163981 0.83 NR4A2 (0.46) MEN1KMT2ACHEK2NR4A2F2
SCHEMBL1768785 0.82 AKR1C3 (0.74) MEN1KMT2AAKR1C3PARP10SRD5A2
SCHEMBL28060732 0.82 KMT2A (0.66) MEN1KMT2AAKR1C3PARP15PARP10
SCHEMBL1263102 0.82 MEN1 (0.47) MEN1KMT2AAKR1C3CHEK2NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
EP-2297103-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS Bristol-Myers Squibb Company (US) 2011-03-23 EP disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 MEN1 4410/4885KMT2A 2948/4885AKR1C3 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.